semaglutide alzheimers AAN 2026 Obesity drug semaglutide fails to

over time, need more of the drug to get the same effect

The market is experiencing exponential growth due to blockbuster drugs like Ozempic, Wegovy, and Mounjaro, rising obesity rates, and favorable clinical outcomes across multiple indications

Fasting glucose, HbA1c, lipid panel, liver function, and kidney markers provide context for individual risk and therapeutic potential

Even if Tirzepatide seems like the stronger option, it may not be covered by your insurance

Your body can only absorb a certain amount of water per hour, and excess is simply excreted

However, survodutide is further along in clinical development with Phase 3 trials fully enrolled and FDA Breakthrough Therapy Designation for MASH, where it has shown strong efficacy